Kyowa Hakko Kirin U.S. Subsidiary Licenses Antibody Technology
This article was originally published in PharmAsia News
Japan's Kyowa Hakko Kirin subsidiary in the United States has licensed the technology behind its Potelligent technology to another U.S. firm for mass-producing antibodies
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.